PRENETICS GLOBAL LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.86 USD | -1.68% |
|
+1.97% | +0.50% |
| Jun. 18 | Earnings Flash (PRE) PRENETICS LIMITED Posts Q1 Revenue $6.4M | MT |
| Jun. 18 | Prenetics Global Limited Announces Board Appointments | CI |
Financials (USD)
| Sales 2024 * | 35.4M | Sales 2025 * | 90M | Capitalization | 72.81M |
|---|---|---|---|---|---|
| Net income 2024 * | -43M | Net income 2025 * | -8M | EV / Sales 2024 * | 2.06 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.81 x |
| P/E ratio 2024 * |
-1.8
x | P/E ratio 2025 * |
-10.6
x | Employees | 322 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 68.43% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.92% | ||
| 1 week | +1.97% | ||
| Current month | +0.33% | ||
| 1 month | -0.34% | ||
| 3 months | +48.86% | ||
| 6 months | +16.46% | ||
| Current year | +0.50% |
1 week
5.86
6.33
1 month
5.506.50
Current year
2.857.84
1 year
2.8513.54
3 years
2.85131.25
5 years
2.85131.25
10 years
2.85131.25
| Managers | Title | Age | Since |
|---|---|---|---|
Chi Hung Tzang
FOU | Founder | 50 | 13-12-31 |
Sheng Wu Yeung
CEO | Chief Executive Officer | 45 | 13-12-31 |
Hoi Chun Lo
DFI | Director of Finance/CFO | 39 | 17-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wing Kwan Chiu
BRD | Director/Board Member | 44 | 22-05-17 |
Sheng Wu Yeung
CEO | Chief Executive Officer | 45 | 13-12-31 |
Yin Pan Cheng
BRD | Director/Board Member | 36 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-10 | 5.86 | -1.68% | 1 625 |
| 24-07-09 | 5.96 | -0.33% | 70,248 |
| 24-07-08 | 5.98 | 0.00% | 28,074 |
| 24-07-05 | 5.98 | +2.66% | 10,417 |
| 24-07-03 | 5.825 | +0.26% | 12,170 |
Delayed Quote Nasdaq, July 10, 2024 at 11:10 am EDT
More quotes
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients.
Calendar
2024-09-05
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
5.96
USD
Average target price
9
USD
Spread / Average Target
+51.01%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.50% | 72.81M | |
| -38.86% | 8.14B | |
| +1.44% | 3.38B | |
| -5.47% | 2.11B | |
| -27.52% | 1.81B | |
| -21.66% | 1.63B | |
| +13.44% | 1.01B | |
| +19.00% | 763M | |
| -9.83% | 690M | |
| -28.16% | 522M |
- Stock Market
- Equities
- PRE Stock
